Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, SEPT. 08, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA (AE-BK), SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL TOPLINE RESULTS OF THE CHAPTER-3 PIVOTAL PHASE 3 STUDY EVALUATING DEUCRICTIBANT EXTENDED-RELEASE (XR) TABLET FOR THE PREVENTION OF HAE ATTACKS. THE PRIMARY ENDPOINT AND ALL SECONDARY EFFICACY ENDPOINTS WERE MET WITH STATISTICAL SIGNIFICANCE. DATA FROM THE CHAPTER-3 STUDY WILL SERVE AS THE BASIS FOR MARKETING AUTHORIZATION APPLICATIONS, WHICH ARE PLANNED TO BE SUBMITTED STARTING IN THE FIRST HALF OF 2027.

PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM CHAPTER-3 PIVOTAL STUDY OF DEUCRICTIBANT XR FOR PROPHYLAXIS OF HAE ATTACKS

ZUG, SWITZERLAND, SEPT. 03, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA, SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), SUMMARIZED THE ORAL AND POSTER PRESENTATIONS FROM THE BRADYKININ SYMPOSIUM 2026, WHICH WILL TAKE PLACE FROM SEPTEMBER 3-4, 2026, IN BERLIN, GERMANY.

PHARVARIS PRESENTS TRANSLATIONAL, NONCLINICAL, AND CLINICAL DATA AT BRADYKININ SYMPOSIUM 2026

ZUG, SWITZERLAND, AUG. 12, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA (AE-BK), SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDING ON JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

PHARVARIS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ZUG, SWITZERLAND, AUG. 06, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA, SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THAT RESULTS FROM THE FIRST IN-DEPTH QUALITATIVE STUDY ASSESSING THE EXPERIENCES OF PEOPLE WITH AAE-C1INH AND VALIDATING RELEVANT PATIENT-REPORTED OUTCOME (PRO) MEASURES HAVE BEEN PUBLISHED IN FRONTIERS IN IMMUNOLOGY. THE STUDY FINDINGS DIRECTLY INFORMED THE DESIGN OF AND ENDPOINT SELECTION FOR THE ONGOING PHASE 3 CREAATE STUDY (NCT07266805) INVESTIGATING DEUCRICTIBANT FOR THE PROPHYLAXIS AND ON-DEMAND TREATMENT OF AAE-C1INH ATTACKS.

ASSESSMENT OF AAE-C1INH DISEASE BURDEN AND VALIDATION OF CLINICAL TRIAL ENDPOINTS PUBLISHED IN FRONTIERS IN IMMUNOLOGY

ZUG, SWITZERLAND, JULY 22, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE PUBLICATION OF A COMPREHENSIVE REVIEW ARTICLE IN CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY PROVIDING A STATE-OF-THE-ART OVERVIEW OF THE BIOLOGY OF BRADYKININ AND THE BRADYKININ B2 RECEPTOR (B2R), AND SUMMARIZING THE GROWING BODY OF EVIDENCE SUPPORTING B2R ANTAGONISM AS A THERAPEUTIC STRATEGY FOR BRADYKININ-MEDIATED DISEASES. DRAWING ON DECADES OF SCIENTIFIC AND CLINICAL RESEARCH, THE ARTICLE TRACES THE EVOLUTION OF BRADYKININ B2 RECEPTOR ANTAGONISM FROM FOUNDATIONAL DISCOVERIES IN KININ BIOLOGY TO A CLINICALLY VALIDATED THERAPEUTIC APPROACH.

PUBLICATION IN CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY SUMMARIZES DECADES OF EVIDENCE SUPPORTING BRADYKININ B2 RECEPTOR AS A VALIDATED THERAPEUTIC TARGET IN BRADYKININ-MEDIATED ANGIOEDEMA

ZUG, SWITZERLAND, JULY 06, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR DEUCRICTIBANT IMMEDIATE-RELEASE (IR) CAPSULE (20 MG) FOR THE ON-DEMAND TREATMENT (ODT) OF HEREDITARY ANGIOEDEMA (HAE) ATTACKS. THE FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF APRIL 23, 2027.

PHARVARIS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR DEUCRICTIBANT IR FOR ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS

ZUG, SWITZERLAND, JUNE 15, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA, SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), SUMMARIZED THE PRESENTATIONS FROM THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) ANNUAL CONGRESS 2026, WHICH TOOK PLACE FROM JUNE 12-15, 2026, IN ISTANBUL, TURKEY.

DATA SUPPORTING DIFFERENTIATED PROFILE OF DEUCRICTIBANT IN HAE MANAGEMENT PRESENTED AT EAACI 2026

ZUG, SWITZERLAND, JUNE 11, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ANNUAL GENERAL MEETING OF SHAREHOLDERS WILL TAKE PLACE ON FRIDAY, JUNE 26, 2026, AT 16:00 CEST (10:00 A.M. EDT).

PHARVARIS ANNOUNCES ANNUAL GENERAL MEETING OF SHAREHOLDERS

ZUG, SWITZERLAND, MAY 29, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF ONE ABSTRACT FOR ORAL PRESENTATION AND SEVEN ABSTRACTS FOR FLASH TALK/POSTER PRESENTATION AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) ANNUAL CONGRESS 2026, TO BE HELD FROM JUNE 12-15, 2026, IN ISTANBUL, TURKEY.

PHARVARIS TO PRESENT CLINICAL DATA AT THE EAACI ANNUAL CONGRESS 2026

TOPLINE DATA FROM CHAPTER-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT XR FOR THE PROPHYLAXIS OF HAE ATTACKS, EXPECTED IN 3Q2026 TIMELINE FOR SUBMISSION OF NDA OF DEUCRICTIBANT IR FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS REMAINS ON-TRACK IN 1H2026 ENROLLMENT ONGOING IN CREAATE, A PIVOTAL STUDY OF DEUCRICTIBANT FOR THE PROPHYLACTIC AND ON-DEMAND TREATMENT OF AAE-C1INH ATTACKS CASH AND CASH EQUIVALENTS OF 247 MILLION AS OF MARCH 31, 2026; SUBSEQUENT CLOSING OF $132 MILLION UNDERWRITTEN OFFERING EXTENDS CASH RUNWAY INTO 2028 ZUG, SWITZERLAND, MAY 12, 2026 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED IN MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE. IN 2026, PHARVARIS REMAINS FOCUSED ON EXECUTION ACROSS OUR LATE-STAGE PROGRAMS, INCLUDING REPORTING CHAPTER-3 DATA IN THE THIRD QUARTER AND ENROLLING IN CREAATE, AND ON ESTABLISHING OUR COMMERCIAL INFRASTRUCTURE IN PREPARATION FOR THE POTENTIAL LAUNCH OF DEUCRICTIBANT IR, SAID BERNDT MODIG, CHIEF EXECUTIVE OFFICER OF PHARVARIS.

PHARVARIS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ZUG, SWITZERLAND, MAY 11, 2026 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (PHARVARIS, NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN OFFERING OF 4,455,863 ORDINARY SHARES (WHICH INCLUDES THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE UP TO AN ADDITIONAL 581,199 ORDINARY SHARES). THE GROSS PROCEEDS TO PHARVARIS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $132.3 MILLION. ALL SHARES IN THE OFFERING WERE SOLD BY PHARVARIS.

PHARVARIS ANNOUNCES CLOSING OF $132.3 MILLION UNDERWRITTEN OFFERING OF ORDINARY SHARES AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

Pharvaris N.V.

PHVS

Price

Financial Reports

No items found.

Press Releases

Pharvaris N.V.

PHVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PHVS